Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q4 2023 call → NOWe need to determine if the phenomenon described in the question is present in the transcript. The phenomenon is: management repeatedly redirects attention away from the conventional yardstick and toward a different part of the business that is already earning today, and indicates that the record has not caught up. Let's analyze the transcript. The company is CollPlant Biotechnologies, a regenerative medicine company. The call covers Q4 and full year 2023 results. The CEO, Yehiel Tal, discusses various programs: dermal filler with AbbVie, regenerative breast implants, gut-on-a-chip, and collaborations with Stratasys. The CFO, Eran Rotem, reviews financials. The question asks: does management repeatedly redirect attention away from the measure or storyline by which the company is conventionally judged and toward a different part of the business that it says is already earning today, and does management indicate that this different part is not yet what the company's reported results or outside understanding reflect? We need to identify the conventional yardstick. For a biotech company like CollPlant, the conventional yardstick might be the progress of its lead product candidates, R&D milestones, or perhaps its revenue from product sales. But the company has a partnership with AbbVie for a dermal filler, which is in clinical phase. The company also has other programs. The question is about redirecting attention to a different part that is already earning. What could that be? Possibly the sales of its rhCollagen products? Or the bioinks? Or the collaboration with Stratasys? But the transcript shows that the company's revenues for 2023 were $11 million, mainly from AbbVie milestone payment. The company's main focus is on the dermal filler with AbbVie, which is in clinical phase. The company also has breast implants in development. The CEO talks about the dermal filler as "our top focus" and it's in clinical phase. He also talks about breast implants, which are in large animal studies. He mentions the gut-on-a-chip program being put on hold. He mentions the collaboration with Stratasys for bioprinting. The question is about redirecting attention to a different part that is already earning. Is there any part that is already earning? The company has sales of its rhCollagen products, bioinks, etc. But the CEO does not seem to be redirecting attention to that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.